chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Kind of sweaty but they sweat a lot.; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (Kind of sweaty but they sweat a lot.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Apr-2021, the patient experienced HYPERHIDROSIS (Kind of sweaty but they sweat a lot.). At the time of the report, HYPERHIDROSIS (Kind of sweaty but they sweat a lot.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications information was reported. No treatment medications were provided.   Most recent FOLLOW-UP information incorporated above includes: On 28-Jun-2021: Patient had her second dose in May with no adverse reactions.Updated outcome of event.
On 9/17/09 received varicella, PREVNAR, HIB. Varicella + PCV on the L arm. Developed extensive cellulitis, fever to 103, required IV Abx. 1o/8/09 records received: DC Summary received 10/8/2009 for DOS 9/19-9/20/2009. DC DX Lt arm Cellulitis 2 Y/O who received multiple vaccines day prior to admission. Presented to ER 9/18/2009 with c/o's lt arm redness and swelling and febrile at 103. Patient tx'd with oral ABX but returned to ER 9/19/2009, still febrile at 101 and with increasing area of redness lt arm. Tx'd with IV ABX and dc'd afebrile.
2nd dose a week apart from 1st dose; This case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too short in a 16-year-old female patient who received Men B NVS (Bexsero) (batch number abxb37aa, expiry date 31st July 2022) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis.   Concomitant products included MENINGOCOCCAL B VACCINE (BEXSERO).   On 31st May 2022, the patient received the 2nd dose of Bexsero and Bexsero Pre-Filled Syringe Device. On 31st May 2022, unknown after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 30-Jan-2023 Reporter's comment: The registered nurse reported that the another nurse administered the 2nd dose of Bexsero a week apart from 1st dose. The reporter consented to follow-up. Additional supportive information: The patient received the 2nd dose of Bexsero earlier than the recommended interval, which led to shortening of vaccination schedule.
On 01/17/04 child had low grade fever (99) was covered with 100 or more papules.  The fever and these continued for 2 days and then faded.  Nothing since.
nausea, headache, heat in back of head, water offered, symptoms improved, pt went home
Side Effects; This case was reported by a consumer via sales rep and described the occurrence of adverse drug reaction in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced adverse drug reaction. On an unknown date, the outcome of the adverse drug reaction was unknown.   It was unknown if the reporter considered the adverse drug reaction to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as per the vaccine indication. The patient experienced side effects after receiving vaccine. The patient asked for how many days the side effects occur.
awoke to severe red eyes; have severe inflammation in my joints, neck, wrist, elbows, knees, hips; have severe inflammation in my joints, neck, wrist, elbows, knees, hips; the pain increased and actually became debilitation/EXTREMELY painful; the pain increased and actually became debilitation; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 58-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), vaccinated at age of 58 years old, dose 2 via an unspecified route of administration, administered in Arm Left on 28Sep2021 12:00 AM (Batch/Lot Number: FF2587) as DOSE 2, SINGLE for covid-19 immunisation. Medical history included hashimotos, hypothyroidism, erythema multiform, and covid prior vaccination. The patient was not pregnant at time of vaccination. Concomitant medications included levothyroxine; liothyronine sodium (CYTOMEL) and vitamins. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: FC3183), vaccinated at age of 58 years old, on 25Aug2021 in left arm for covid-19 immunisation. Three weeks after 2nd shot (28Sep2021), on 19Oct2021 08:00 AM, patient awoke to severe red eyes and started to have severe inflammation in her joints, neck, wrist, elbows, knees, hips. The pain increased and actually became debilitation. Patient needed help to do the smallest things. Extremely painful. Increased until she went for emergency help at a Hospital. Events resulted in doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Prolongation of existing hospitalization (vaccine received during existing hospitalization), Life threatening illness (immediate risk of death from the event). Treatment was received and treatment was corticosteroid shots+ 3 days IV Methylprednisolone. The patient was hospitalized for 3 days. The patient underwent lab tests and procedures which included Antigen SARS: negative blood test on 02Nov2021. The outcomes of events were unknown.  The events ocular hyperaemia, arthritis, dermatitis, pain and asthenia occurred in a location different from that of the reporter. This may be a duplicate report if another reporter from the location where the event occurred has submitted the same information to his/her local agency.
This is a spontaneous report from a contactable. A 68-years-old non-pregnant female patient received bnt162b2 (Solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration on an unspecified date (at the age of 68-year-old) as DOSE 1, SINGLE, dose 2 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as DOSE 2, SINGLE, dose 3 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as DOSE 3 (BOOSTER), SINGLE for covid-19 immunization. Medical history included blood cholesterol increased from an unknown date and unknown if ongoing, osteopenia from an unknown date and unknown if ongoing, drug hypersensitivity from an unknown date and unknown if ongoing. Concomitant medication(s) included gabapentin (GABAPENTIN) taken for an unspecified indication, start and stop date were not reported; atenolol (ATENOLOL) taken for an unspecified indication, start and stop date were not reported; calcium carbonate, colecalciferol (CALCIUM + D3 [CALCIUM CARBONATE;COLECALCIFEROL]) taken for an unspecified indication, start and stop date were not reported. On 01Mar2021the patient experienced diminished taste. The outcome of event was not recovered.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Systemic: Abdominal Pain-Severe, Systemic: Cardiac Disorder (diagnosed by MD)-Severe, Systemic: Diarrhea-Severe, Systemic: Hypotension-Severe, Systemic: Tachycardia-Severe, Systemic: Vomiting-Medium, Additional Details: colostomy patient, explosive diarrhea started within 15  hours of vaccine, continued and turned to vomiting, primary md said use immodium, than then said go to hospital, at hospital was diagnoised with tachycardia/AFib, and blood pressure dropped very low.  Hospital ran tests and could not find a cause other than combo of flu and covid vaccine administration.
Employee received vaccine at 1100. At 1400, rash developed on the chest and tongue and lips were swollen. Took Benadryl 25mg and symptoms resolved.
Approximately 2.5 weeks after receiving my second dose of Pfizer COVID Vaccine my body developed blood clots and I was hospitalized
Patient reported being unable to lift arm beginning the evening of 10/1/21 and still experiencing pain on 10/4/21 although able to lift her arm above her head.
Localized swelling and redness and a hard lump; little itchy bumps. On both arms and both injection sites.
Chest pain; Chills; Fatigue; A spontaneous report was received from a consumer concerning a female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced chills, fatigue and chest pain.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 10 Feb 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: Unknown) through unknown route for prophylaxis of COVID-19 infection.  On 10 Feb 2021, the patient experienced fatigue and chills. On 11 Feb 2021, the patient experienced chest pain.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of events was unknown.
PATIENT HAD RASH ON NECK AND UNDER BREAST AREA--IN THE FOLD AND CREASE AREA.   AROUND THE NECK -THE LEFT SIDE GOT IT MORE THEN THE RIGHT SIDE.  SAME UNDER THE BREAST. IT WAS MORE ON THE LEFT SIDE IT WAS MORE THAN THE RIGHT SIDE.-  PATIENT NOTICED THE LEFT SIDE WAS WORSE. PATIENT PUT DESITIN UNDER THE BREAST.  DR. TOLD HER TO PUT LOTION SO PATIENT GOT CALAMINE LOTION ON IT AND TO TAKE BENADRYL.    TODAY 3/26 IT HAS GOTTEN BETTER, STILL THERE BUT IT IS BETTER.
Right side of neck, face, and head tender skin that hurts to the touch and when air blows in that area.
Information has been received from a pharmacist referring to an unspecified patient of unknown age and unknown gender. Information about pertinent medical history, concurrent conditions and drug reactions/allergies was not provided. Concomitant medication included sterile diluent. On 15-JAN-2019, the patient inadvertently received an expired dose of VARIVAX (injection, lot number: N001528, expiration date: 13-JAN-2019; strength, frequency and route unspecified) for prophylaxis. Lot number and expiration for sterile diluent injection used to reconstitute the vaccine were reported as N030026, expiration date 04-JUN-2020. No adverse effects were reported.
A fever days after the vaccine. Patient ended up in the hospital with a high fever and to this day he suffers with joint pain and stiffness.
It began with a small swollen area on the upper arm near the injection site that was painful. Diagnosed with Arthus Reaction on 9/12/2012. Progressed to large swollen, tender, red area and caused sinusitis to become aggravated and then lead to bronchitis. Grew to 3.5" wide and 4.5" tall in size. Required treatment with Prednisone and antibiotics to resolve on 9/13/2012. Patient began feeling less swelling but still pain on 9/14/2012.
Child had seizure 7 hours after 2nd dose of flu vaccine; Patient went to Hospital and was admitted. 3/5/09 MR received for DOS 1/13/09 with D/C DX:  Vaccine Reaction. Pt presented with seizure-like activity of unresponsiveness, eyes rolling back and stiffness.  PE WNL in ED. No further activity. D/C home.
Right after vaccine, approximately 1 hour,  I felt very weak and my had a rapid heartbeat. My arm swelled at the injection site and was very painful. I felt my shot was given above where it should have been. The pain continued throughout the day. I did have limited range of motion in my arm. The next day, my arm continued to hurt with redness at the injection site. I had went to the doctor and got an examination. My pain continued for over a week.
July 25 I felt bad my throat got sore and this was the second time I got COVID-19 and it felt pretty similar to the first time. I had coughing and my nose just ran nonstop, and my sides were sore due to the coughing. I also lost my taste and smell. This was strange because I just put hot sauce all over my food and I could taste the spicy seasoning but nothing else. I tested myself. Aug 2 I started to feel better than I waited until 5 days passed which made it August 8th and I was then negative for COVID-19. Oct 26 I was still testing positive according to the hospital. On October 29 I finally tested negative.
Body aches and chills led to low-grade fever (100 degrees at peak) and headache over the course of midnight to 9:30 a.m. the following day. Treated by hydrating.
Painful Urination; blood in urine; This spontaneous case was reported by a consumer and describes the occurrence of DYSURIA (Painful Urination) and BLOOD URINE PRESENT (blood in urine) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Mar-2021, the patient experienced DYSURIA (Painful Urination) and BLOOD URINE PRESENT (blood in urine). At the time of the report, DYSURIA (Painful Urination) and BLOOD URINE PRESENT (blood in urine) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No concomitant medications were provided.   No treatment details were provided.
This case was reported by a physician via sales rep and described the occurrence of headache in an unspecified number of patients who received BEXSERO for prophylaxis. On an unknown date, the patient received BEXSERO at an unknown dose. On an unknown date, unknown after receiving BEXSERO, the patient experienced headache and chills. On an unknown date, the outcome of the headache and chills were recovered/resolved. It was unknown if the reporter considered the headache and chills to be related to BEXSERO. Additional details were reported as follows: The age at vaccination was not reported for the patients. The reporter stated that many of his patients that had received BEXSERO complained of headaches and chills. The side effects last about 2 days. The reporter said he would withhold vaccination if a patient had a school exam the following day. The reporter did agree to follow up from GlaxoSmithKline.
Severe case of shingles erupted within 12 hrs of receiving shot - $ 350.00 for shot plus emergency room visit. Was told that a blood test is available that with tell if zoster virus exists in the body (by friends who also came down w/ shingles) is this true.
I had the shot and still go them twice / Suspected vaccination failure; I had the shot and still go them twice; This case was reported by a consumer via media and described the occurrence of suspected vaccination failure in a adult patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The patient had reported the case for himself/herself. The age at vaccination was not reported. The age group was not reported but was captured as an adult as per vaccine indication.  The patient received Shingles vaccine shot and still got shingles twice. This case was considered as suspected vaccination failure since the details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting. The follow-up would not possible, as no contact details were available.
Dose administered to 4 patients past 30 days in refrigerator.; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered to 4 patients past 30 days in refrigerator.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered to 4 patients past 30 days in refrigerator.). On 18-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Dose administered to 4 patients past 30 days in refrigerator.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was mentioned. No treatment medication was mentioned.   This case was linked to MOD-2021-355911, MOD-2021-355908 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 21-Oct-2021: Follow up received on 21-Oct-2021 contains non significant information.
Case received from a healthcare professional on 13 and 14-Sep-05 (MIS/VIS reference numbers # 05-0447 and 05-0453).  A 43-year-old female patient, with history of diverticulitis, had received an injection of DECAVAC (lot # U1215AA, on right deltoid) on 22-Jul-05 and 1 day later, she complained of fever, rash confined to arm, headache, nausea, fatigue, body aches and sore arm.  It was reported that the vaccine was given with a 1" needle.  The patient recovered on 28-Jul-05.  Follow up information received on 17/Nov/2005.  As per responsible physician there is no further information for this case.
DIZZINESS; This spontaneous report received from a patient concerned a 28 year old female. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included patient had no known drug allergies. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805018, expiry: UNKNOWN) dose was not reported, administered on 05-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 05-MAR-2021, the subject experienced dizziness. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from dizziness. This report was non-serious.
Client was vaccinated for Covid with Pfizer vaccines in February 2021.  Developed symptoms on 10/13/2021: runny nose, congestion, myalgia.  Tested positive for Covid with PCR on 10/15/2021.
Tingling @ inject site & feeling of vax migrating are reported in pt recvd 1 dose of flu vax;
Fever chills nausea vomiting muscle and joint pain lasting 4 days. Swelling of armpit since first two weeks after  2-13-21 and still swollen as of 9-13-21 Triggered migraine
This spontaneous case was reported by a patient and describes the occurrence of ILLNESS (Made the patient sick) in a patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis. No Medical History information was reported. On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (Made the patient sick). At the time of the report, ILLNESS (Made the patient sick) outcome was unknown. The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown. No concomitant medications was reported. It was reported that the patient really thought that lawsuit was selfish, the patient had not thought you know, and mentioned thank God Moderna was not in the patient. It was further reported that bad business and patients should turn the vaccine away for Pfizer. No treatment drug details was reported.
Acute Pain in upper arm, shoulder; limited range of motion and weakness in left shoulder for 72 hours following administration.  No swelling or pain at injection site.
Shortly after the second vaccination shot, I was feeling unwell and had major body aches and headaches for approx 4 days afterwards. I also had the feeling of a sinus infection that would not stop. About 11 days later I woke up with double vision and could not see properly. My left eye was fully dilated and visibly tilted to a different direction than my right. I went to the hospital and they did several tests and are unsure about what exactly is wrong and caused this and say that it is very rare. They shows in the MRI that there is a cavernous angioma in my brain and they think it is causing the eye issues. My other eye also has unusual blurry distance vision. While in the hospital they tried using 2 different steroids that did not seem to work. They discharged me from the hospital and basically just said to wait and they think it might possibly start to get better in a month. I am not sure what to do at this point and I'm worried it may be a result of the vaccine.
Information has been received from a registered nurse concerning an unspecified patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies and concurrent conditions were not informed. On an unknown date, the patient was vaccinated with an improperly stored dose of VAQTA lot # reported as L023939, expiration date 15-MAR-2017, (dosage and therapy route were not provided). Concomitant therapies were not informed. The VAQTA was exposed to 33F for 48 hours. It was informed that there was no previous excursions and it was a call due to data logger. No adverse effects were reported. No product quality complaint (PQC) was involved. Lot # L023939 is not valid for hepatitis A vaccine, inactivated. Additional information has been requested.
Initial consumer report received on 18 Feb 2010; this patient with a medical history of asthma, was vaccinated with H1N1 (batch no 102047P1) on 02 Jan 2010. On 24 Jan 2010, she began to experience bruising, paleness, difficulty breathing, and petechiae all over her legs. On 27 Jan 2010, she was hospitalized and diagnosed with idiopathic thrombocytopenic purpura and was hospitalized. The patient now needs to use an inhaler a couple of time a day, although she has not needed to use an inhaler in the past several years before receiving the H1N1 injection. The patient's platelets were 2000, and white blood cells were at 1.5 (date unspecified). The patient was reported as very scratchy. The patient was currently taking prednisone.